What is CordAdvantage?
CordAdvantage has the potential to significantly enhance cord blood banking. Currently under development at Americord’s Research and Development facility in upstate New York, this new technology is capable of harvesting even more stem cells than can be harvested in a typical umbilical cord blood collection today.
By increasing the stem cell yield, CordAdvantage dramatically extends the usefulness of preserved stem cells. Until now, obtaining a large volume of cord blood rich with HSCs from the placenta has been difficult, limiting the use of such stem cells to persons weighing 65 pounds or less. CordAdvantage resolves what had previously been a limiting factor in stem cell treatments.
Saving Cells Means Saving Lives
Stem cells from umbilical cord blood in the placenta are identical to stem cells from cord blood in the umbilical cord. This type of stem cell has been used in the treatment of over 80 rare blood diseases and has been proposed for use in treating hundreds of other diseases and disorders.
When Will CordAdvantage Be Available?
Americord is committed to pioneering innovations that will help families today and tomorrow. Our researchers are working hard to bring this new advancement to parents as soon as possible. Be among the first to hear news about Americord, as well as the current benefits of our cord bank registry, when you sign up for our free Information Kit.